Lilly's Shared Topline Results for Retevmo (selpercatinib) Versus Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly and Company (NYSE:LLY) announced positive topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC). The study met its primary endpoint, showing a significant and clinically meaningful improvement in progression-free survival (PFS).
August 22, 2023 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's successful LIBRETTO-531 study results could potentially boost the company's stock in the short term as it indicates a positive development in their product pipeline.
Positive clinical trial results often lead to increased investor confidence, potentially driving up the stock price. The successful results of the LIBRETTO-531 study indicate a positive development in Eli Lilly's product pipeline, which could attract more investors and boost the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100